J. Ferlay, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, vol.13, issue.5, pp.359-386, 2015.
DOI : 10.1016/S1470-2045(12)70137-7

B. Escudier, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up??, Annals of Oncology, vol.25, issue.suppl 3, pp.49-56, 2014.
DOI : 10.1093/annonc/mdu259
URL : https://academic.oup.com/annonc/article-pdf/23/suppl_7/vii65/6674212/mds227.pdf

A. Sciarra, The emerging role of targeted therapy in renal cell carcinoma (RCC): Is it time for a neoadjuvant or an adjuvant approach?, Critical Reviews in Oncology/Hematology, vol.81, issue.2, pp.151-162, 2012.
DOI : 10.1016/j.critrevonc.2011.02.003

N. B. Haas, Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial, The Lancet, vol.387, issue.10032, pp.2008-2016, 2016.
DOI : 10.1016/S0140-6736(16)00559-6

R. Passalacqua, Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-?? (IFN-??) in Operable Renal Cell Carcinoma (RCC), Journal of Immunotherapy, vol.37, issue.9, pp.440-447, 2014.
DOI : 10.1097/CJI.0000000000000055

B. C. Leibovich, Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma, Cancer, vol.20, issue.12, pp.2566-2575, 2003.
DOI : 10.1002/cncr.11851

P. E. Clark, The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy, Kidney International, vol.76, issue.9, pp.939-945, 2009.
DOI : 10.1038/ki.2009.296

J. Brugarolas, PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma, The Cancer Journal, vol.19, issue.4, pp.324-332, 2013.
DOI : 10.1097/PPO.0b013e3182a102d1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222578

M. Seles, Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma, International Journal of Molecular Sciences, vol.24, issue.4, p.17, 2016.
DOI : 10.1016/j.pharmthera.2016.03.004
URL : http://doi.org/10.3390/ijms17040573

M. Deng, Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling, Genomics Data, vol.5, pp.173-175, 2015.
DOI : 10.1016/j.gdata.2015.06.016

Y. Wu, A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls, Oncogenesis, vol.44, issue.2, p.192, 2016.
DOI : 10.1038/nature05503
URL : http://doi.org/10.1038/oncsis.2015.48

R. Flippot, Cancer subtypes classification using long non-coding RNA, Oncotarget, vol.7, issue.33, pp.54082-54093, 2016.
DOI : 10.18632/oncotarget.10213
URL : https://hal.archives-ouvertes.fr/hal-01419223

G. G. Malouf, Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing, Molecular Oncology, vol.287, issue.3, p.7, 2014.
DOI : 10.1074/jbc.M112.368175

B. Rini, A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies, The Lancet Oncology, vol.16, issue.6, pp.676-685, 2015.
DOI : 10.1016/S1470-2045(15)70167-1

M. Tan, Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma, Urology, vol.75, issue.6, pp.1365-1370, 2010.
DOI : 10.1016/j.urology.2009.07.1289

N. B. Haas, Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial., Journal of Clinical Oncology, vol.33, issue.7_suppl, 2015.
DOI : 10.1200/jco.2015.33.7_suppl.403

A. Ravaud, Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy, New England Journal of Medicine, vol.375, issue.23, pp.10-1056, 2016.
DOI : 10.1056/NEJMoa1611406

J. S. Lam, POSTOPERATIVE SURVEILLANCE PROTOCOL FOR PATIENTS WITH LOCALIZED AND LOCALLY ADVANCED RENAL CELL CARCINOMA BASED ON A VALIDATED PROGNOSTIC NOMOGRAM AND RISK GROUP STRATIFICATION SYSTEM, The Journal of Urology, vol.174, issue.2, pp.466-472, 2005.
DOI : 10.1097/01.ju.0000165572.38887.da

B. Delahunt, The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters, The American Journal of Surgical Pathology, vol.37, issue.10, pp.1490-1504, 2013.
DOI : 10.1097/PAS.0b013e318299f0fb

K. J. Livak and T. Schmittgen, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2???????CT Method, Methods, vol.25, issue.4, pp.402-408, 2001.
DOI : 10.1006/meth.2001.1262

P. M. Wierzbicki, Identification of a suitable qPCR reference gene in metastatic clear cell renal cell carcinoma, Tumor Biology, vol.11, issue.6, pp.12473-12487, 2014.
DOI : 10.1186/1471-2199-11-61

S. Dupasquier, Validation of housekeeping gene and impact on normalized gene expression in clear cell Renal Cell Carcinoma: critical reassessment of YBX3/ZONAB/CSDA expression, BMC Molecular Biology, vol.15, issue.1, p.9, 2014.
DOI : 10.1158/0008-5472.CAN-04-1827

H. N. Reich, Molecular Markers of Injury in Kidney Biopsy Specimens of Patients with Lupus Nephritis, The Journal of Molecular Diagnostics, vol.13, issue.2, pp.143-151, 2011.
DOI : 10.1016/j.jmoldx.2010.10.005

M. Jung, In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR, BMC Molecular Biology, vol.8, issue.1, p.47, 2007.
DOI : 10.1186/1471-2199-8-47

Z. Yin, H. Ding, E. He, J. Chen, and M. Li, Overexpression of long non-coding RNA MFI2 promotes cell proliferation and suppresses apoptosis in human osteosarcoma, Oncology Reports, vol.36, issue.4, pp.2033-2040, 2016.
DOI : 10.3892/or.2016.5013

S. Chen, Upregulated expression of long noncoding RNA SNHG15 promotes cell proliferation and invasion through regulates MMP2/MMP9 in patients with GC, Tumor Biology, vol.34, issue.Suppl 2, pp.6801-6812, 2016.
DOI : 10.1007/s13277-013-0842-8

J. Zhang, H. Wei, and H. Yang, Long noncoding RNA SNHG15, a potential prognostic biomarker for hepatocellular carcinoma, Eur. Rev. Med. Pharmacol. Sci, vol.20, pp.1720-1724, 2016.

M. Gerlinger, Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing, Nature Genetics, vol.486, issue.3, pp.225-233, 2014.
DOI : 10.1186/1471-2164-13-591

M. Gerlinger, Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing, New England Journal of Medicine, vol.366, issue.10, pp.883-892, 2012.
DOI : 10.1056/NEJMoa1113205

N. Mcgranahan, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, vol.7, issue.5, pp.1463-1469, 2016.
DOI : 10.1038/nprot.2012.037

T. Janowitz, S. J. Welsh, K. Zaki, P. Mulders, and T. Eisen, Adjuvant Therapy in Renal Cell Carcinoma???Past, Present, and Future, Seminars in Oncology, vol.40, issue.4, pp.482-491, 2013.
DOI : 10.1053/j.seminoncol.2013.05.004
URL : http://doi.org/10.1053/j.seminoncol.2013.05.004

T. G. Kwon, ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC), J. Clin. Oncol, vol.32, p.5, 2014.

M. Choueiri, N. Tannir, and E. Jonasch, Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma, Current Clinical Pharmacology, vol.6, issue.3, pp.144-150, 2011.
DOI : 10.2174/157488411797189415

W. S. Webster, Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival, Cancer, vol.104, issue.1, pp.46-53, 2006.
DOI : 10.1038/nm0902-1039c

D. Y. Heng, Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor???Targeted Agents: Results From a Large, Multicenter Study, Journal of Clinical Oncology, vol.27, issue.34, pp.5794-5799, 2009.
DOI : 10.1200/JCO.2008.21.4809

T. Arita, Circulating long non-coding RNAs in plasma of patients with gastric cancer, Anticancer Res, vol.33, pp.3185-3193, 2013.